Disease · MONDO_0005789
Trials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 31
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Phase 2 | 175 | 2024-07-29 | Chronic Hepatitis Delta | BULEVIRTIDE, INTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT03852719 | Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) | Phase 3 | 150 | 2022-10-28 | Chronic Hepatitis Delta | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03546621 | A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D | Phase 2 | 120 | 2019-12-30 | Chronic Hepatitis D Infection With Hepatitis B | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02577029 | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) | Phase 2 | 79 | 2019-04-12 | Hepatitis B, Hepatitis D | ENTECAVIR, PEGINTERFERON ALFA-2A, TENOFOVIR DISOPROXIL | Its record names the disease | ClinicalTrials.gov |
| NCT00686790 | Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) | Phase 3 | 68 | 2011-01-17 | Hepatitis D, Chronic, Hepatitis B, Chronic | PEGINTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov |
| NCT04535544 | A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus | Phase 2 | 52 | 2024-11-06 | Hepatitis D, Chronic | ENTECAVIR, TENOFOVIR ALAFENAMIDE, TENOFOVIR DISOPROXIL | Its record names the disease | ClinicalTrials.gov |
| NCT02765802 | A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection | Phase 2 | 33 | 2023-01-17 | Hepatitis D, Chronic | PEGINTERFERON LAMBDA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT02732639 | A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) | Phase 3 | 31 | 2016-08-26 | Hepatitis D, Chronic | INTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT02511431 | Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir | Phase 2 | 22 | 2018-05-24 | Hepatitis D | LONAFARNIB, RITONAVIR | Its record names the disease | ClinicalTrials.gov |
| NCT01495585 | Lonafarnib for Chronic Hepatitis D | Phase 2 | 14 | 2016-08-31 | Hepatitis D | LONAFARNIB | Its record names the disease | ClinicalTrials.gov |
| NCT00023322 | Pegylated Interferon to Treat Chronic Hepatitis D | Phase 2 | 13 | 2013-07-10 | Hepatitis D | PEGINTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT02731131 | A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) | Phase 2 | 12 | 2016-07-15 | Hepatitis D, Chronic | PEGINTERFERON ALFA-2A, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT06051045 | Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients | 400 | Chronic Hepatitis D | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05718700 | Study of Bulevirtide in Participants With Chronic Hepatitis D Infection | 170 | Chronic Hepatitis D Infection | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov | ||
| NCT07309380 | Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D | Phase 3 | 150 | Hepatitis D, Chronic | HEPALATIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06903338 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase 3 | 124 | Viral Hepatitis | ELEBSIRAN, TOBEVIBART | Its record names the disease | ClinicalTrials.gov | |
| NCT06122285 | Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD) | 100 | Hepatitis D | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05461170 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | Phase 2 | 95 | Hepatitis D, Chronic | ELEBSIRAN, TOBEVIBART | Its record names the disease | ClinicalTrials.gov | |
| NCT06505928 | A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D | Phase 2 | 90 | Hepatitis D | HEPALATIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05928000 | HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV | 80 | Hepatitis D | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005789/trials